Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of 25 mg vs 100 mg spironolactone on quality of life and outcomes in systolic heart failure
IRCT20220404054403N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of spironolactone (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Quality of life, Left ventricular ejection fraction and 1 more. Started Jul 2022; status: completed.
02
Drugs
spironolactone
Beyond the preview
Go deeper on IRCT20220404054403N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220404054403N1.